^
    2d
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    4d
    Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL (clinicaltrials.gov)
    P2, N=41, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • lenalidomide • Monjuvi (tafasitamab-cxix)
    4d
    Warthin's Tumor Involved by Monoclonal B-Cell Lymphocytosis: A Case Report. (PubMed, Cureus)
    The patient remains asymptomatic and is currently monitored without therapy. This case illustrates the occurrence of CLL-type MBL within the lymphoid stroma of a Warthin's tumor, emphasizing the importance of careful histologic and immunophenotypic evaluation and the need for clearly defined diagnostic criteria for extranodal tissue-based MBL.
    Journal
    |
    CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    7d
    Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial (clinicaltrials.gov)
    P2, N=33, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Aug 2028 --> Jun 2029 | Trial primary completion date: Aug 2028 --> Jun 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)
    8d
    Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Feb 2030 | Trial primary completion date: Dec 2027 --> Feb 2030
    Trial completion date • Trial primary completion date
    |
    Gomekli (mirdametinib)
    8d
    Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. (PubMed, Lancet Haematol)
    In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation.
    P1/2 data • Journal
    |
    TP53 (Tumor protein P53)
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)
    8d
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    9d
    Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    Gomekli (mirdametinib)
    10d
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (PubMed, J Clin Oncol)
    Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.
    P3 data • Journal • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • bendamustine
    11d
    Comprehensive Cytopathologic, Flow Cytometric and Immunocytochemical Analysis of a Challenging Case of Small Cell Variant of Anaplastic Large T-Cell Lymphoma in a Child. (PubMed, Cytopathology)
    The index case report highlights the diagnostic complexities of the small cell variant of ALCL and emphasises the utility of various ancillary techniques like immunophenotyping and FISH, in conjunction with cytomorphology, in confirming such a challenging diagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK rearrangement • TNFRSF8 positive
    14d
    Zanubrutinib and Venetoclax in CLL (ZANU-VEN) (clinicaltrials.gov)
    P2, N=45, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib)
    16d
    FOLLOW: French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Apr 2025
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    BCL2 (B-cell CLL/lymphoma 2)